---
layout: post
title: "Patient-Focused Drug Development for Vitiligo; Public Meeting; Request for Comments"
date: 2026-02-05 19:08:08 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2021-00832
original_published: 2021-01-15 00:00:00 +0000
significance: 8.00
---

# Patient-Focused Drug Development for Vitiligo; Public Meeting; Request for Comments

**Published:** February 05, 2026 19:08 UTC
**Source:** Federal Register
**Original Published:** January 15, 2021 00:00 UTC
**Document Number:** 2021-00832

## Summary

In the Federal Register notice published on March 19, 2020, the Food and Drug Administration (FDA, Agency, or we) announced the cancellation of the public meeting entitled "Patient-Focused Drug Development for Vitiligo" originally scheduled to occur on March 30, 2020, as announced in the Federal Register on February 12, 2020. FDA is announcing a new date for the meeting, to occur in a virtual format. The purpose of the public meeting is to allow FDA to obtain patient perspectives on the impact of vitiligo on daily life, patient views on treatment approaches, and decision factors considered when selecting a treatment.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2021/01/15/2021-00832/patient-focused-drug-development-for-vitiligo-public-meeting-request-for-comments)
- API: https://www.federalregister.gov/api/v1/documents/2021-00832

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
